Erlotinib, the inhibitor of the epidermal growth factor receptor (EGFR) is also entering in phase I clinical trial following preclinical studies which demonstrated that erlotinib prevents HCC development in vivo and reverses the poor-prognosis PLS associated with HCC risk [9, 37]. The gene discussed is EGFR; the disease is hepatocellular carcinoma.